Kate Rogers appointed as Chief Executive Officer of the Follicular Lymphoma foundation (FLF)

Today the Follicular Lymphoma Foundation (FLF) announced that Kate Rogers, currently leading the transformation of Glaxo SmithKline’s global finance organisation, as their new CEO. Kate will assume the role on the 1st July 2022.

The FLF, launched in 2019, is the first patient led foundation to focus solely on helping people with follicular lymphoma (FL) and whose mission is to lead new and determined efforts to find cures for follicular lymphoma.

Kate will be responsible for leading the development of its work including the design and expansion of its research funding, the delivery of its precision medicine programme and its strategic partnership and funding initiatives.

The FLF is an international organisation based in London and is developing a unique model involving a wide range of innovative methodologies.

Kate is currently leading the transformation of Glaxo SmithKline’s global finance organisation having previously worked as CFO for Laboratoire Glaxo SmithKline SaS (GSK France) as well as other senior finance and leadership roles during 20 years with GSK. Kate holds a Bachelor of Science degree in Engineering from Oxford University and qualified as a Chartered Management Accountant in 1999. She also serves as a Non-Executive Director and Chair of the Audit Committee of Ixico Plc.

Nicola Mendelsohn, Founder of the FLF said “I am delighted that Kate will be joining us as CEO at such an important time for the FLF. We are very fortunate to have someone with Kate’s caliber and experience, and she brings a unique level of insight and capability needed to accelerate the global effort to bring cures to this underserved patient group.

I am looking forward to working with Kate and know that her great talent and leadership will advance our mission to find a cure for FL”.

Kate Rogers said “I am honored and excited to lead the FLF at such an exciting time for the organization. Part of my role will be to continue to catalyse the research programmes to accelerate a transformative change in scientific research, that will lead to better treatments and cures for FL patients. My hope is that in the not too distant future, curing this disease for the majority of patients will be a tangible reality”.

The FLF is dedicated to improving lives for the thousands living with FL today and for everyone who is diagnosed tomorrow.

Kate Rogers biography:

Kate Rogers is currently Global Finance Transformation Lead at GSK. She also serves as Non-Executive Director and Audit Committee Chair for Ixico Plc, a Medical Imaging company for Biopharmaceutical clinical research.

Prior to her current role, Kate was CFO for Laboratoire Glaxo SmithKline SaS (GSK France) and has held senior finance, business transformation and leadership roles in GSK over a period of 20 years.

Kate has a degree in Engineering Science from Oxford University and is a Chartered Management Accountant. After graduating from Oxford, Kate joined Unilever as a management trainee, where she developed her early career in commercial finance and change management. From Unilever, Kate joined the pharmaceutical and life sciences industry, and has a deep belief and passion for enabling scientific advances to improve human health.